166 related articles for article (PubMed ID: 1416032)
1. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
Ho JW; Moody DE
Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
[TBL] [Abstract][Full Text] [Related]
2. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
3. A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver.
Osikowska-Evers BA; Eichelbaum M
Life Sci; 1986 May; 38(19):1775-82. PubMed ID: 3702606
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
5. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
6. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
8. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Fonne-Pfister R; Meyer UA
Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
[TBL] [Abstract][Full Text] [Related]
9. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
[TBL] [Abstract][Full Text] [Related]
11. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
Broly F; Vandamme N; Libersa C; Lhermitte M
Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
Otton SV; Inaba T; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
[TBL] [Abstract][Full Text] [Related]
13. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
[TBL] [Abstract][Full Text] [Related]
14. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
16. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
[TBL] [Abstract][Full Text] [Related]
17. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
Woolhouse NM
Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
[No Abstract] [Full Text] [Related]
18. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
[TBL] [Abstract][Full Text] [Related]
19. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo.
Manns M; Zanger U; Gerken G; Sullivan KF; Meyer zum Büschenfelde KH; Meyer UA; Eichelbaum M
Hepatology; 1990 Jul; 12(1):127-32. PubMed ID: 2373473
[TBL] [Abstract][Full Text] [Related]
20. Debrisoquine/sparteine-type polymorphic drug metabolism in wild Clethrionomys rufocanus.
Hoshi H; Masuda M; Yamamoto Y; Suimamoto Y; Kazusaka A; Fujita S
Drug Metab Dispos; 1995 Nov; 23(11):1301-3. PubMed ID: 8591735
[No Abstract] [Full Text] [Related]
[Next] [New Search]